R
RDG
vs
W
WIG20
Over the past 12 months, RDG has underperformed WIG20, delivering a return of +30% compared to the WIG20's +33% growth.
Stocks Performance
RDG vs WIG20
Performance By Year
RDG vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Read Gene SA
Glance View
Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The firm operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.